India’s Section 3(d): The Definitive IP Strategy Guide for Pharmaceutical and Biotech Companies
A technical deep dive for pharma IP teams, R&D leads, and institutional investors on the world’s most consequential pharmaceutical patent […]
September 2018
U.S. vs. China Pharmaceutical Patent Strategy: The Definitive Analyst’s Guide to IP Valuation, Enforcement, and Competitive Positioning
A comparative deep dive for pharma and biotech IP teams, R&D leads, and institutional investors navigating the two most consequential
Maximizing Pharmaceutical Patent Longevity: A Mechanistic and Strategic Guide to IP Term Extension and Lifecycle Fortification
The Economic Imperative of Time In the pharmaceutical sector, time is a tangible asset with a valuation that often exceeds
